A detailed history of Parallel Advisors, LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 465 shares of ADPT stock, worth $2,594. This represents 0.0% of its overall portfolio holdings.

Number of Shares
465
Previous 465 -0.0%
Holding current value
$2,594
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$2.88 - $4.8 $60 - $100
-21 Reduced 4.32%
465 $1,000
Q4 2023

Feb 09, 2024

SELL
$3.46 - $5.33 $899 - $1,385
-260 Reduced 34.85%
486 $2,000
Q3 2023

May 20, 2024

SELL
$5.07 - $8.44 $1,232 - $2,050
-243 Reduced 24.57%
746 $4,000
Q3 2023

Nov 13, 2023

SELL
$5.07 - $8.44 $1,232 - $2,050
-243 Reduced 24.57%
746 $4,000
Q2 2023

May 20, 2024

SELL
$6.19 - $8.78 $2,123 - $3,011
-343 Reduced 25.75%
989 $6,000
Q2 2023

Aug 04, 2023

SELL
$6.19 - $8.78 $2,123 - $3,011
-343 Reduced 25.75%
989 $6,000
Q1 2023

May 20, 2024

BUY
$7.8 - $10.11 $6,762 - $8,765
867 Added 186.45%
1,332 $11,000
Q1 2023

Apr 25, 2023

BUY
$7.8 - $10.11 $1,450 - $1,880
186 Added 16.23%
1,332 $11,000
Q4 2022

Feb 03, 2023

BUY
$6.26 - $9.34 $1,577 - $2,353
252 Added 28.19%
1,146 $8,000
Q3 2022

Nov 10, 2022

BUY
$6.5 - $12.67 $513 - $1,000
79 Added 9.69%
894 $6,000
Q2 2022

Aug 01, 2022

BUY
$6.4 - $14.73 $1,926 - $4,433
301 Added 58.56%
815 $7,000
Q1 2022

Apr 28, 2022

BUY
$10.12 - $28.9 $293 - $838
29 Added 5.98%
514 $7,000
Q4 2021

Jan 20, 2022

BUY
$25.17 - $36.85 $377 - $552
15 Added 3.19%
485 $14,000
Q1 2021

Apr 23, 2021

BUY
$37.26 - $67.74 $17,512 - $31,837
470 New
470 $19,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $797M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.